Latest Pneumococcal conjugate vaccine Stories
The World Health Organization (WHO) has now approved a new cervical cancer vaccine from pharmaceutical company GlaxoSmithKline.
Infants who received two or three primary doses of the 7-valent pneumococcal conjugate vaccine (PCV-7) both had a decreased rate of carrying pneumococcal microorganisms that can cause pneumonia and other infections, compared to infants who were not vaccinated, according to a study in the July 8 issue of JAMA.
The Bill & Melinda Gates Foundation and the governments of Britain, Italy, Canada, Russia and Norway announced a $1.5 billion initiative on Friday to provide poor nations better access to vaccines against pneumococcal disease such as meningitis and pneumonia.
A $1.5 billion plan to save the world's poorest children from pneumococcal diseases was activated Friday in Lecce, Italy, international aid groups said. Representatives of five countries and four international aid groups officially made good on commitments promised in 2007 to speed delivery of pneumococcal vaccines that kill 1.6 million people year, including an estimated 1 million children under age 5. Italy donated $635 million, Britain $485 million, Canada $200 million, Russia $80 million,...
COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most prevalent serotypes associated with pneumococcal disease (PD), the leading cause of vaccine-preventable death in children younger than five worldwide.
WASHINGTON, June 4 /PRNewswire-USNewswire/ -- The U.S. Agency for International Development (USAID) yesterday contributed $75 million to improve and expand children's immunization programs in developing countries. The contribution is part of the overall U.S.
WAYNE, Pa., May 7 /PRNewswire-FirstCall/ -- Encorium Group, Inc.
-- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- COLLEGEVILLE, Pa., May 7 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S.
Infants who receive the pneumococcal conjugate vaccine (PCV) following the combination vaccine for diphtheria, polio, tetanus, pertussis and Haemophilus influenzae type b (DPTaP-Hib vaccine) appear to experience less pain than those who are immunized in the opposite order.
- 2009 First Quarter Reported Diluted Earnings per Share were $0.89, Consistent with the Prior Year, and Diluted Earnings per Share, Excluding Certain Significant Items, Increased 1% to $0.95 - Worldwide Net Revenue Decreased 6% for the 2009 First Quarter and Increased 2%, Excluding the Impact of Foreign Exchange - First Quarter Net Revenue Growth, Excluding the Impact of Foreign Exchange, was Driven by Increases of 23% for Enbrel (outside the U.S.